Chairman Rick Scott and Ranking Member Kirsten Gillibrand of the U.S. Senate Special Committee on Aging have announced a hearing scheduled for October 8, 2025, focusing on the risks associated with America’s reliance on foreign-manufactured generic drugs. The hearing, titled “Bad Medicine: Closing Loopholes that Kill American Patients,” aims to address concerns about drug safety and accessibility, particularly for older Americans.
The committee intends to explore legislative and regulatory measures to strengthen the domestic production of generic drugs. Testimony will be provided by several expert witnesses, including Tony Sardella, Founder & Chair of API Innovation Center; Tony Paquin, President & CEO of iRemedy Healthcare, Inc.; Andrew Rechenberg, Economist at Coalition for a Prosperous America; and Marta Wosinska, Ph.D., Senior Fellow at the Brookings Institution’s Center on Health Policy.
The session will discuss strategies such as reshoring pharmaceutical manufacturing, increasing transparency in the supply chain, implementing country of origin labeling requirements, and addressing loopholes like the Acetris loophole that may impact drug safety.
The hearing is set to take place at 3:15 PM in room SH-216 of the Hart Senate Office Building. A live broadcast will be available online.
